lilly semaglutide vials Eli launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient option for taking the drug: They can Eli Lilly Launches Cheaper Single-Use

Investigations are guided by clinical suspicion rather than routine panels: for example, thyroid function tests and ferritin may be checked if symptoms suggest deficiency or thyroid disease, while an androgen profile may be appropriate in women presenting with menstrual irregularity, hirsutism, or acne

Gastrointestinal side effects compound the problem Nausea affects 44% of semaglutide users and 28% of tirzepatide users in clinical trials

However, BPC-157 lacks the comprehensive antioxidant gene transcriptomic signature that GHK-Cu demonstrates its antioxidant effects are more contextually secondary to angiogenesis and anti-inflammation

Source: Jastreboff et al., NEJM 2023